<?xml version="1.0" encoding="UTF-8"?>
<p>According to the WHO, the most promising candidate for treatment of SARS-COV-2 is remdesivir (
 <xref rid="B50" ref-type="bibr">50</xref>, 
 <xref rid="B51" ref-type="bibr">51</xref>). Remdesivir is a nucleotide analog that acts against SARS-CoV-2 by inhibiting RNA polymerase and has the following advantages: a broad spectrum antiviral; efficacy against coronaviruses, both 
 <italic>in vitro</italic> and 
 <italic>in vivo</italic> studies; a safety profile demonstrated in Ebola studies; and a higher efficacy than the combination lopinavir/ritonavir/IFN Î² (Interferon beta) used in animal model studies (
 <xref rid="B36" ref-type="bibr">36</xref>, 
 <xref rid="B45" ref-type="bibr">45</xref>).
</p>
